Standard
The Treat-to-Target Project in Atopic Dermatitis : One Year On. / de Bruin-weller, Marjolein; Deleuran, Mette; Biedermann, Tilo; Bissonnette, Robert; Foley, Peter; Girolomoni, Giampiero; Hercogová, Jana; Hong, Chih Ho; Katoh, Norito; Pink, Andrew E.; Richard, Marie Aleth; Shumack, Stephen; Silvestre, Juan F.; Thyssen, Jacob P.; Weidinger, Stephan.
I:
Acta Dermato-Venereologica, Bind 103, adv5382, 2023.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
de Bruin-weller, M, Deleuran, M, Biedermann, T, Bissonnette, R, Foley, P, Girolomoni, G, Hercogová, J, Hong, CH, Katoh, N, Pink, AE, Richard, MA, Shumack, S, Silvestre, JF
, Thyssen, JP & Weidinger, S 2023, '
The Treat-to-Target Project in Atopic Dermatitis: One Year On',
Acta Dermato-Venereologica, bind 103, adv5382.
https://doi.org/10.2340/actadv.v103.5382APA
de Bruin-weller, M., Deleuran, M., Biedermann, T., Bissonnette, R., Foley, P., Girolomoni, G., Hercogová, J., Hong, C. H., Katoh, N., Pink, A. E., Richard, M. A., Shumack, S., Silvestre, J. F.
, Thyssen, J. P., & Weidinger, S. (2023).
The Treat-to-Target Project in Atopic Dermatitis: One Year On.
Acta Dermato-Venereologica,
103, [adv5382].
https://doi.org/10.2340/actadv.v103.5382Vancouver
de Bruin-weller M, Deleuran M, Biedermann T, Bissonnette R, Foley P, Girolomoni G o.a.
The Treat-to-Target Project in Atopic Dermatitis: One Year On.
Acta Dermato-Venereologica. 2023;103. adv5382.
https://doi.org/10.2340/actadv.v103.5382Author
de Bruin-weller, Marjolein ; Deleuran, Mette ; Biedermann, Tilo ; Bissonnette, Robert ; Foley, Peter ; Girolomoni, Giampiero ; Hercogová, Jana ; Hong, Chih Ho ; Katoh, Norito ; Pink, Andrew E. ; Richard, Marie Aleth ; Shumack, Stephen ; Silvestre, Juan F. ; Thyssen, Jacob P. ; Weidinger, Stephan. / The Treat-to-Target Project in Atopic Dermatitis : One Year On. I: Acta Dermato-Venereologica. 2023 ; Bind 103.
Bibtex
@article{7b79edb7ed2243e08d98ad438d889101,
title = "The Treat-to-Target Project in Atopic Dermatitis: One Year On",
abstract = "Atopic dermatitis is a chronic skin condition for which a range of systemic treatments have recently been approved. A treat-to-target strategy has been deve-loped previously alongside an algorithm to guide the management of patients with atopic dermatitis. Here, we review the strategy and algorithm in the context of the evolving therapeutic landscape, and identify areas for further refinement and development.",
keywords = "atopic dermatitis, consensus, systemic treatment, treat-to-target",
author = "{de Bruin-weller}, Marjolein and Mette Deleuran and Tilo Biedermann and Robert Bissonnette and Peter Foley and Giampiero Girolomoni and Jana Hercogov{\'a} and Hong, {Chih Ho} and Norito Katoh and Pink, {Andrew E.} and Richard, {Marie Aleth} and Stephen Shumack and Silvestre, {Juan F.} and Thyssen, {Jacob P.} and Stephan Weidinger",
note = "Funding Information: Pharma, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharma, Gal-derma, Roche, and Sanofi, outside the submitted work. GG has received personal fees from AbbVie, Almirall, Amgen, Biogen, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Fresenius Kabi, Galderma, Genzyme, LEO Pharma, Novartis, Pfizer, Rege-neron, Samsung and Sanofi. JH has attended advisory boards for Sanofi Genzyme, LEO Pharma and UCB; has acted as an investigator in clinical studies sponsored by Diasorin and Eli Lilly; and has received speaker fees from UCB, Janssen, Sanofi-Aventis, Eli Lilly, Novartis and AbbVie. C-HH has received honoraria as a speaker/consultant for AbbVie, Amgen, Bausch Health, Celgene, Eli Lilly, Galderma, Glaxo-Smith-Kline, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, and UCB; and has received grants as an investigator from AbbVie, Amgen, Bausch Health, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Dermavant, Eli Lilly, Galderma, Glaxo-Smith-Kline, Incyte, Janssen, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB, outside the submitted work. NK has received honoraria as a speaker/consultant for AbbVie, Celgene Japan, Janssen Pharma, Kyowa Kirin, LEO Pharma, Eli Lilly Japan, Maruho, Mitsubishi Tanabe Pharma, Sanofi, Taiho Pharmaceutical, and Torii Pharmaceutical, and has received grants as an investigator from AbbVie, A2 Healthcare, Boehringer Ingel-heim Japan, Eisai, Janssen Pharma, Kyowa Kirin, LEO Pharma, Eli Lilly Japan, Maruho, Sun Pharma, Taiho Pharmaceutical, and Torii Pharmaceutical. AEP has acted as an advisor, speaker, investigator or received educational support from: Sanofi, AbbVie, Eli Lilly, Pfizer, Galderma, Novartis, Almirall, La-Roche Posay, LEO, UCB, BMS, Amgen, Celgene, Novartis, and Janssen. SS has received honoraria as a speaker/consultant for Sanofi and has received institutional research grants as an investigator from Sanofi, outside of submitted work. JS reports institutional grants for investigator-initiated research from the German GBA, the BMG, BMBF, EU, Federal State of Saxony, Novartis, Sanofi, ALK, and Pfizer. He also participated in advisory board meetings as a paid consultant for Sanofi, Eli Lilly, and ALK. JT is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, a speaker for AbbVie, Almirall, Eli Lilly, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, and received research grants from Pfizer, Regeneron, and Sanofi-Genzyme. SW is the co-principal investigator of the German Atopic Eczema Registry (TREATgermany) and coordinator of the EU/IMI project BIOMAP (BIOMarkers in Atopic dermatitis and Psoriasis) projects and is an investigator in a number of clinical trials in atopic dermatitis and psoriasis sponsored by a wide range of pharmaceutical companies; has received institutional research grants from Sanofi, LEO Pharma and L{\textquoteright}Or{\'e}al; has acted as a consultant for Sanofi, Regeneron, LEO Pharma, Eli Lilly, AbbVie, Pfizer, Incyte and Novartis; and has lectured at educational events sponsored by Sanofi, Regeneron, LEO Pharma, AbbVie and Galderma, outside of submitted work. Publisher Copyright: {\textcopyright} 2023, Medical Journals/Acta D-V. All rights reserved.",
year = "2023",
doi = "10.2340/actadv.v103.5382",
language = "English",
volume = "103",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato - Venereologica",
}
RIS
TY - JOUR
T1 - The Treat-to-Target Project in Atopic Dermatitis
T2 - One Year On
AU - de Bruin-weller, Marjolein
AU - Deleuran, Mette
AU - Biedermann, Tilo
AU - Bissonnette, Robert
AU - Foley, Peter
AU - Girolomoni, Giampiero
AU - Hercogová, Jana
AU - Hong, Chih Ho
AU - Katoh, Norito
AU - Pink, Andrew E.
AU - Richard, Marie Aleth
AU - Shumack, Stephen
AU - Silvestre, Juan F.
AU - Thyssen, Jacob P.
AU - Weidinger, Stephan
N1 - Funding Information:
Pharma, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharma, Gal-derma, Roche, and Sanofi, outside the submitted work. GG has received personal fees from AbbVie, Almirall, Amgen, Biogen, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Fresenius Kabi, Galderma, Genzyme, LEO Pharma, Novartis, Pfizer, Rege-neron, Samsung and Sanofi. JH has attended advisory boards for Sanofi Genzyme, LEO Pharma and UCB; has acted as an investigator in clinical studies sponsored by Diasorin and Eli Lilly; and has received speaker fees from UCB, Janssen, Sanofi-Aventis, Eli Lilly, Novartis and AbbVie. C-HH has received honoraria as a speaker/consultant for AbbVie, Amgen, Bausch Health, Celgene, Eli Lilly, Galderma, Glaxo-Smith-Kline, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, and UCB; and has received grants as an investigator from AbbVie, Amgen, Bausch Health, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Dermavant, Eli Lilly, Galderma, Glaxo-Smith-Kline, Incyte, Janssen, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB, outside the submitted work. NK has received honoraria as a speaker/consultant for AbbVie, Celgene Japan, Janssen Pharma, Kyowa Kirin, LEO Pharma, Eli Lilly Japan, Maruho, Mitsubishi Tanabe Pharma, Sanofi, Taiho Pharmaceutical, and Torii Pharmaceutical, and has received grants as an investigator from AbbVie, A2 Healthcare, Boehringer Ingel-heim Japan, Eisai, Janssen Pharma, Kyowa Kirin, LEO Pharma, Eli Lilly Japan, Maruho, Sun Pharma, Taiho Pharmaceutical, and Torii Pharmaceutical. AEP has acted as an advisor, speaker, investigator or received educational support from: Sanofi, AbbVie, Eli Lilly, Pfizer, Galderma, Novartis, Almirall, La-Roche Posay, LEO, UCB, BMS, Amgen, Celgene, Novartis, and Janssen. SS has received honoraria as a speaker/consultant for Sanofi and has received institutional research grants as an investigator from Sanofi, outside of submitted work. JS reports institutional grants for investigator-initiated research from the German GBA, the BMG, BMBF, EU, Federal State of Saxony, Novartis, Sanofi, ALK, and Pfizer. He also participated in advisory board meetings as a paid consultant for Sanofi, Eli Lilly, and ALK. JT is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, a speaker for AbbVie, Almirall, Eli Lilly, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, and received research grants from Pfizer, Regeneron, and Sanofi-Genzyme. SW is the co-principal investigator of the German Atopic Eczema Registry (TREATgermany) and coordinator of the EU/IMI project BIOMAP (BIOMarkers in Atopic dermatitis and Psoriasis) projects and is an investigator in a number of clinical trials in atopic dermatitis and psoriasis sponsored by a wide range of pharmaceutical companies; has received institutional research grants from Sanofi, LEO Pharma and L’Oréal; has acted as a consultant for Sanofi, Regeneron, LEO Pharma, Eli Lilly, AbbVie, Pfizer, Incyte and Novartis; and has lectured at educational events sponsored by Sanofi, Regeneron, LEO Pharma, AbbVie and Galderma, outside of submitted work.
Publisher Copyright:
© 2023, Medical Journals/Acta D-V. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Atopic dermatitis is a chronic skin condition for which a range of systemic treatments have recently been approved. A treat-to-target strategy has been deve-loped previously alongside an algorithm to guide the management of patients with atopic dermatitis. Here, we review the strategy and algorithm in the context of the evolving therapeutic landscape, and identify areas for further refinement and development.
AB - Atopic dermatitis is a chronic skin condition for which a range of systemic treatments have recently been approved. A treat-to-target strategy has been deve-loped previously alongside an algorithm to guide the management of patients with atopic dermatitis. Here, we review the strategy and algorithm in the context of the evolving therapeutic landscape, and identify areas for further refinement and development.
KW - atopic dermatitis
KW - consensus
KW - systemic treatment
KW - treat-to-target
U2 - 10.2340/actadv.v103.5382
DO - 10.2340/actadv.v103.5382
M3 - Journal article
C2 - 37083095
AN - SCOPUS:85153423259
VL - 103
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
SN - 0001-5555
M1 - adv5382
ER -
